Stay updated on Niraparib vs Physician's Choice in BRCA+ Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Niraparib vs Physician's Choice in BRCA+ Breast Cancer Clinical Trial page.

Latest updates to the Niraparib vs Physician's Choice in BRCA+ Breast Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedA site-wide NIH notice about the transition from “Artificial Intelligence” to “Super Intelligence” appears above the page, and the site revision changes to v3.7.2. The study record itself still displays a 403 error.SummaryDifference1%

- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe ClinicalTrials.gov study page still displays a 403 Forbidden error. Its footer revision label changes from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check36 days agoChange DetectedAccess to the study record NCT01905592 is blocked by a 403 Forbidden error, removing the study details and locations from the page. Users are presented with a 403 error page instead of the expected study information.SummaryDifference18%

- Check43 days agoChange DetectedPage revision updated from v3.6.6 to v3.7.0, representing a refreshed version of the page. The exact textual or UI changes are not specified in the provided data.SummaryDifference0.0%

- Check50 days agoChange DetectedAdded Tel Litwinsky, Israel, 52621 as a new study site and removed Qiryat Krinitzi, Israel, 52621. This updates the study's participating locations in Israel.SummaryDifference0.1%

- Check57 days agoChange DetectedIsrael site list updated: Tel Litwinsky (52621) removed and Qiryat Krinitzi (52621) added. Document revision updated from v3.6.5 to v3.6.6.SummaryDifference0.1%

Stay in the know with updates to Niraparib vs Physician's Choice in BRCA+ Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Niraparib vs Physician's Choice in BRCA+ Breast Cancer Clinical Trial page.